TechnipFMC plc Ordinary Share vs GSK plc — how do they compare? TechnipFMC plc Ordinary Share trades at $69.99 (market cap $27.31B), while GSK plc trades at $46.82 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.4× TechnipFMC plc Ordinary Share's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold TechnipFMC plc Ordinary Share for 0 Days and GSK plc for 93 Days on average.
| FTI | GSK | |
|---|---|---|
Market Cap | $27.31B | $91.88B |
Volume | 2,496,410 | 7,730,529 |
Sector | Energy | Health |
52-Week High | $80.08 | $61.18 |
52-Week Low | $35.57 | $43.24 |
Typical Hold Time | 0 Days | 93 Days |
Enterprise Value | $27.56B | $111.88B |
Dividend Yield | 0.29% | 3.9% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
TechnipFMC is an energy technology company providing subsea systems, surface technologies, and related services across the life of oil and gas fields. Its offerings include equipment, controls, installation support, and digital tools for offshore and onshore projects.
Read more on FTI →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →